Skip to main navigation

Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.

Accept and Close

Advanced therapies for the sports medicine and severe burn care markets

In the News

About Vericel
Vision Mission & Values Patient Stories Executive Leadership Team Extended Leadership Team Board of Directors Vericel History Partnering with Vericel Corporate Compliance
Advanced Therapies
MACI Epicel NexoBrid Patents
Clinical Development
Pipeline Clinical Trials Clinical and Scientific Publications Grants
Careers
Open Positions Vericel Benefits
Investor Relations
Press Releases Events & Presentations Quarterly Results Stock Quote & Analyst Coverage Annual Reports & Proxies Statements ESG Report SEC Filings Corporate Governance Board of Directors FAQ Email Alerts Contact

Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

SEC Filing Details

Document Details

Form

144/A

Filing Date

Dec 7, 2023

Document Date

Dec 7, 2023

Form Description

Amendment to a previously filed 144

Filing Group

Other

Company

Vericel Corporation

Issuer

VERICEL CORP

Filing Formats

View HTML

Download PDF

Download DOC

Download XLS

Day High:
Day Low:
Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Presentation

Company Presentation 2.6 MB

Terms and Conditions of Use | Privacy Policy | Community Guidelines | Medical Information Request Form

Vericel^® and the Vericel logo are registered trademarks of Vericel Corporation.
©2024 Vericel Corporation. All Rights Reserved.
Vericel Corporation 64 Sidney Street, Cambridge, MA 02139
Phone: (617) 588-5555 • Fax: (617) 588-5554 • mail@vcel.com